Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

A new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a ...

AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval from the FDA for a lung cancer indication, seven months after ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...